Skip to main content

Prostate Cancer: Combination Androgen Deprivation Therapy for High Risk or Very High Risk Prostate Cancer

CBE ID
0390
1.5 Project
Endorsement Status
1.0 New or Maintenance
1.1 Measure Structure
Previous Endorsement Cycle
Is Under Review
No
1.6 Measure Description

Percentage of patients, regardless of age, with a diagnosis of prostate cancer at high or very high risk of recurrence receiving external beam radiotherapy to the prostate who were prescribed androgen deprivation therapy in combination with external beam radiotherapy to the prostate

    Measure Specs
      General Information
      1.7 Measure Type
      1.3 Electronic Clinical Quality Measure (eCQM)
      1.9 Care Setting
      1.20 Types of Data Sources
      1.14 Numerator

      Patients who were prescribed androgen deprivation therapy in combination with external beam radiotherapy to the prostate

      1.15 Denominator

      All patients, regardless of age, with a diagnosis of prostate cancer at high or very high risk of recurrence receiving external beam radiotherapy to the prostate

      Exclusions

      Denominator Exceptions:
      Documentation of medical reason(s) for not prescribing/administering androgen deprivation therapy in combination with external beam radiotherapy to the prostate (eg, salvage therapy)

      Documentation of patient reason(s) for not prescribing/administering androgen deprivation therapy in combination with external beam radiotherapy to the prostate

      Most Recent Endorsement Activity
      Measure Retired and Endorsement Removed Cancer Project 2015-2016
      Initial Endorsement
      Last Updated
      Removal Date
      Steward Organization
      American Urological Association
      Steward POC email
      spope@auanet.org
      Steward Organization Copyright

      The AUAER and PCPI shall jointly hold all rights on the Measure, including copyright, in perpetuity, in all forms and media throughout the world, for the full term of copyright, including renewals. Notwithstanding the foregoing, the Measure will be available to the public free of charge for use in non-commercial endeavors without seeking any permissions (notices on the measures provide this permission, e.g., use by health care providers in connection with their practices is not a commercial use).

                Public Comments